IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
(one-quar ter the low est ap proved dose) as the side ef fects are dose de pend ent, along with the two most
commonly used doses of candesartan (4 and 8mg).
Com pe ti tion: Novartis also ob tained ap proval in Ja pan for its Co-DIO, com bin ing its Diovan (valsartan)
with hy dro chlo ro thi a zide in Jan u ary 2009. Both join Banyu’s losartan + hy dro chlo ro thi a zide com bi na tion
Preminent al though this is avail able in one strength only com pared with two strengths for Takeda’s
Ecard and Novartis’ Co-DIO. Co-DIO how ever uses two dos ages of hy dro chlo ro thi a zide (6.25mg and
12.5mg) along with the same dose of valsartan which it says will en able cli ni cians to se lect the more ap -
pro pri ate one con sid er ing the risk of ad verse events due to hy dro chlo ro thi a zide. Takeda con firmed that
data from clin i cal tri als re vealed com pa ra ble hypotensive ef fi cacy with Ecard (4mg candesartan +
6.25mg hy dro chlo ro thi a zide) to candesartan 8mg and a more po tent hypotensive ef fect using Ecard
(8mg + 6.25mg hydrochlorothiazide) to candesartan 8mg.
Takeda’s Blopress was the third best sell ing AIIA in its class (C9C, To tal An gio ten sin II An tag o nists, Plain)
in the 12 months to Sep tem ber 2008, with 11.4% mar ket share and 6% dol lar growth, ac cord ing to IMS.
Novartis’ (Swit zer land) Diovan (valsartan) is mar ket leader with a 26.3% mar ket share and 12% dol lar
growth; Merck & Co’s (USA) Cozaar (losartan) is sec ond with a 16.3% mar ket share, down 5% over the
pre vi ous year, and in fourth place, Boehringer Ingelheim’s (Ger many) Micardis (irbesartan), with a
8.9% mar ket share and 16% dol lar growth. Benicar (olmesartan medoxmil) took fifth place with 8.5%
and 24% growth.
Sales/An a lyst Com ment: In the year to March 31 2008 (fis cal 2007) ac cord ing to Takeda, con sol i -
dated Blopress global sales were up 8.2% to Yen223.1 bil lion. In the 12-month pe riod to the end of Sep -
tem ber 2008, Blopress Comp was Takeda’s num ber nine in ter na tional phar ma ceu ti cal prod uct, mak ing
up 1.3% of cor po rate sales, up 7% in fixed rate dol lar terms, ac cord ing to IMS. An a lysts at Mor gan Stan -
ley (Au gust 2008) fore cast con sol i dated Blopress sales of Yen246.8 bil lion by the year ending March
2013.
CALSLOT (manidipine), a once-daily cal cium an tag o nist, was launched in Ja pan in 1990 for hy per ten -
sion.
Li cens ing: Manidipine was li censed-out to Chiesi (It aly) for mar ket ing in Eu rope and Brazil. Takeda
co-mar kets the prod uct in It aly with Chiesi as Vascoman. Chiesi first launched it in It aly as Iperten in
1996. In 2000, Chiesi launched it in Brazil as Manivasc. Chiesi com pleted the Eu ro pean mu tual rec og ni -
tion pro ce dure in 2001, and in 2003, launched manidipine in Spain as Artedil and in Greece as Manyper.
It was launched in Ger many as Manyper in and in Tu ni sia as Iperten in 2004. In 2005, it was launched in
France as Iperten. Iperten was launched in Mo rocco in March 2006.
Lifecycle Man age ment: Li censee Chiesi has de vel oped a com bi na tion of the Takeda ACE in hib i tor
delapril and manidipine, with the trade name Vi vace. It was launched in Aus tria in 2005 and in Ger many
in Feb ru ary 2006. In March 2006, it was launched in Brazil as Hipertil. Delapril, and manidipine were
orig i nally de vel oped by Takeda, and li censed by Chiesi for Eu rope and Brazil. Takeda does not ap pear to
be de vel op ing this com bi na tion product in Japan, however.
Sales/An a lyst Com ment: With sales of Yen5 bil lion in fis cal 2007 (end ing March 2008), an a lysts at
Mor gan Stan ley (Au gust 2008) fore cast a drop in sales to Yen3.5 bil lion by the year end ing March 2013.
NIASPAN (ni a cin ex tended re lease) is ap proved a treat ment of mul ti ple lipid dis or ders, and was first
launched in 1997. It is the only once-daily ex tended-re lease for mu la tion of ni a cin avail able in the USA for
this indication.
Li cens ing: Takeda (through TPNA) signed an agree ment with Kos (now Abbott, USA) in No vem ber 2003
to co-pro mote the prod uct in the USA from Jan u ary 2004. An iden ti cal agree ment was signed for Kos’s
other cho les terol prod uct, Advicor (ni a cin/lovastatin ex tended re lease). Both agree ments are due to last
© 2009 IMS Health In cor po rated or its af fil i ates Page 44